This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tilby, M. J. Articles by Dean, C. J. Search for Related Content PubMed PubMed Citation Articles by Tilby, M. J. Articles by Dean, C. J.

Sensitive Detection of DNA Modifications induced by Cisplatin and Carboplatin in Vitro and in Vivo Using a Monoclonal Antibody¹

Experimental Unit, Section of Medicine [M. J. T., C. J., J. C., C. J. D.], and Molecular Pharmacology Unit, Section of Drug Development [R. J. K., J. J. R.], Institute of Cancer Research, Sutton, Surrey, England, SM2 5NG

An assay that is based upon a monoclonal antibody (ICR4) is described that enables the quantitation of cisplatin-induced adducts on DNA down to 3 nmol Pt/g DNA (i.e., 1 Pt adduct/10⁶ bases), the level necessary to produce toxic effects in cells in vitro and in vivo, using just a few micrograms of DNA. Detection is possible below this level (although probably not necessary for in vivo studies) but the cross-reactivity of unmodified DNA sequences complicates absolute quantitation of adducts. Therefore, it will be possible to investigate the distribution of clinically useful platinum drugs in patients undergoing chemotherapy. Rats of strain F344 appeared to be the best, among several tested, for the production of antibodies to modified DNA, and they were used for the production of hybridomas. Fifteen hybridomas which secreted antibodies that bound to DNA that was highly modified with cisplatin but not to normal DNA were obtained. One (ICR4) was chosen for further characterization because of its relatively strong binding to DNA modified to a moderate level with cisplatin. The characterization included the development of a sensitive competitive enzyme-linked immunoabsorbent assay and the use of DNA that had been reacted with cisplatin both in vitro and in vivo. The levels of platination of both types of DNA samples were determined by atomic absorbance spectroscopy. For DNA that had been exposed to cisplatin in vitro, 50% inhibition of antibody binding was caused by about 15 fmol of total DNA-bound Pt/assay well. At moderate levels of platination, heating of the DNA solution at 100°C for 5 min increased its immunoreactivity such that 50% inhibition was caused by 2.5 fmol Pt adducts/well. Pt adducts on DNA extracted from cells that had been treated with cisplatin were less immunoreactive than DNA treated with cisplatin in vitro, but after heating the immunoreactivity increased such that 50% inhibition in the assay was caused by 2 fmol Pt adduct/well. This sensitivity was invariant over a wide range of levels of platinum adduct frequency. DNA adducts formed by the second generation anticancer drug carboplatin were recognized similarly to the adducts formed by cisplatin, but those formed by the clinically inactive trans-diamminedichloroplatinum(II) or chloro(diethylenetriamine)-platinum(II)-chloride were not significantly immunoreactive. Control DNA cross-reacted in the competitive assay but the immunoreactivity per mol base was 10⁷ times lower than the immunoreactivity of cisplatin adducts.

¹ This work was funded by the U.K. Cancer Research Campaign.

² To whom requests for reprints should be addressed.

³ Professor John J. Roberts died on October 10, 1990.

Received 6/29/90. Accepted 10/ 9/90.

This article has been cited by other articles:

				Involvement of the HER2 pathway in repair of DNA damage produced by chemotherapeutic agents Mol. Cancer Ther., November 1, 2009; 8(11): 3015 - 3023.

				B. Liedert, D. Pluim, J. Schellens, and J. Thomale Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei. Nucleic Acids Res., January 1, 2006; 34(6): e47 - e47. [Abstract] [Full Text] [PDF]

				K. A. Gould, C. Nixon, and M. J. Tilby p53 Elevation in Relation to Levels and Cytotoxicity of Mono- and Bifunctional Melphalan-DNA Adducts Mol. Pharmacol., November 1, 2004; 66(5): 1301 - 1309. [Abstract] [Full Text] [PDF]

				D. A. Solomon, M. C. Cardoso, and E. S. Knudsen Dynamic targeting of the replication machinery to sites of DNA damage J. Cell Biol., August 16, 2004; 166(4): 455 - 463. [Abstract] [Full Text] [PDF]

				T. Mueller, W. Voigt, H. Simon, A. Fruehauf, A. Bulankin, A. Grothey, and H.-J. Schmoll Failure of Activation of Caspase-9 Induces a Higher Threshold for Apoptosis and Cisplatin Resistance in Testicular Cancer Cancer Res., January 15, 2003; 63(2): 513 - 521. [Abstract] [Full Text] [PDF]

				I. U. De Silva, P. J. McHugh, P. H. Clingen, and J. A. Hartley Defects in interstrand cross-link uncoupling do not account for the extreme sensitivity of ERCC1 and XPF cells to cisplatin Nucleic Acids Res., September 1, 2002; 30(17): 3848 - 3856. [Abstract] [Full Text] [PDF]

				G. J. Veal, C. Dias, L. Price, A. Parry, J. Errington, J. Hale, A. D. J. Pearson, A. V. Boddy, D. R. Newell, and M. J. Tilby Influence of Cellular Factors and Pharmacokinetics on the Formation of Platinum-DNA Adducts in Leukocytes of Children Receiving Cisplatin Therapy Clin. Cancer Res., August 1, 2001; 7(8): 2205 - 2212. [Abstract] [Full Text] [PDF]

				K. E. Knudsen, D. Booth, S. Naderi, Z. Sever-Chroneos, A. F. Fribourg, I. C. Hunton, J. R. Feramisco, J. Y. J. Wang, and E. S. Knudsen RB-Dependent S-Phase Response to DNA Damage Mol. Cell. Biol., October 15, 2000; 20(20): 7751 - 7763. [Abstract] [Full Text]

				M. W. Strobeck, K. E. Knudsen, A. F. Fribourg, M. F. DeCristofaro, B. E. Weissman, A. N. Imbalzano, and E. S. Knudsen BRG-1 is required for RB-mediated cell cycle arrest PNAS, July 5, 2000; 97(14): 7748 - 7753. [Abstract] [Full Text] [PDF]

				N. T. Le Gac, G. Villani, and P. E. Boehmer Herpes Simplex Virus Type-1 Single-strand DNA-binding Protein (ICP8) Enhances the Ability of the Viral DNA Helicase-primase to Unwind Cisplatin-modified DNA J. Biol. Chem., May 29, 1998; 273(22): 13801 - 13807. [Abstract] [Full Text] [PDF]

				P. J. Webster, K. Ng, P. Snitch, S. L. Jones, N. Amos, and P. R. Hamett Does determination of tissue platinum levels by mass spectroscopy have potential for monitoring exposure of pharmacy personnel to platinum-based antineoplastic drugs? A pilot study Journal of Oncology Pharmacy Practice, December 1, 1995; 1(4): 41 - 48. [Abstract] [PDF]